Study of stem cell transplant for systemic sclerosis in youth
Treatments studied
Part of Heart & circulation, Lungs & breathing, Skin clinical trials.
This Phase 2 study tests whether an “autologous” stem cell transplant—using your own stem cells—can reduce systemic sclerosis disease activity. It is mainly for children, teens, and young adults whose disease did not improve despite standard medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your parent/guardian) can sign consent in writing, with child/youth agreement if able
- Your age is 8 to 24 at the time you sign
- You were diagnosed with systemic sclerosis when you were 19 or younger
- Your disease did not improve or got worse after at least 2 disease-modifying arthritis medicines within the last year
- A heart (cardiology) check says you can safely do a stem cell transplant
- In blood/virus tests, you must not have HIV, hepatitis B, or hepatitis C
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests an autologous stem cell transplant (a treatment using your own blood-forming stem cells) for severe systemic sclerosis or severe lupus. The goal is to reset the immune system to help control the autoimmune disease.
This trial tests a new cell injection treatment (RY_SW01) for people with systemic sclerosis (a condition causing skin thickening and organ issues). It aims to see if the therapy can improve skin hardening and overall symptoms.
This early safety study tests whether an intravenous (through a vein) stem cell product made from donated umbilical cord cells is safe for people with systemic sclerosis. If you join, the goal is to see how your body tolerates the treatment and monitor for side effects.
This clinical trial is testing if infusions of special stem cells (called mesenchymal stem cells) can help people with certain autoimmune diseases where standard treatments have not worked well enough. It is an early-phase study in Pakistan for adults (and some children for one condition) with rheumatoid arthritis, lupus, systemic sclerosis, ankylosing spondylitis, or dermatomyositis/polymyositis.
This study tests a new type of cell therapy (CAR T-cells) to see if it works better than current treatments for active systemic sclerosis. It is designed for people whose lung disease is not well controlled by standard therapy.
This study looks at skin cells and immune cells in people with systemic sclerosis to better understand what drives the disease. Your participation may help researchers learn how the immune system and skin support cells change over time.
Hear when a new Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.